| 原发性肝癌患者介入治疗前后SE-CAD,CA19-9和VEGF水平的变化 |
| |
| 引用本文： | 杨华喜. 原发性肝癌患者介入治疗前后SE-CAD,CA19-9和VEGF水平的变化[J]. 标记免疫分析与临床, 2007, 14(1): 4-6 |
| |
| 作者姓名： | 杨华喜 |
| |
| 作者单位： | 怀化市第二人民医院检验科,湖南,怀化,418200 |
| |
| 摘 要： | 为探讨原发性肝癌患者介入治疗前后,血清可溶性上皮钙粘蛋白(SE-CAD),糖类抗原19-9(CA19-9)和血管内皮生长因子(VEGF)水平的变化,本文应用RIA测定了32例患者血清CA19-9的水平,ELASA测定SE-CAD和VEGF水平,并与35名健康人相比较.患者介入治疗前后SE-CAD,CA19-9和VEGF水平明显高于正常组(P＜0.01).介入治疗后30例中,有20例在6个月以后没有复发,患者血清三项指标回落至正常范围,介入治疗后6个月,10例复发患者血清SE-CAD,CA19-9和VEGF水平的变化与患者的病情和愈后密切相关,有一定的实用价值.
|
| 关 键 词： | 原发性肝癌 糖类抗原19-9 可溶性上皮钙粘蛋白 血管内皮生长因子 |
| 文章编号： | 1006-1703(2007)01-0004-03 |
| 修稿时间： | 2006-07-12 |
Changes of Serum SE-CAD, CA19-9 and VEGF Levels in Patients with Primary Hepatic Cancer Before and After Intervention Therapy |
| |
| YANG Hua-xi. Changes of Serum SE-CAD, CA19-9 and VEGF Levels in Patients with Primary Hepatic Cancer Before and After Intervention Therapy[J]. Labeled Immunoassays and Clinical Medicine, 2007, 14(1): 4-6 |
| |
| Authors: | YANG Hua-xi |
| |
| Abstract: | To explore the changes of serum SE-CAD,CA19-9 and VEGF levels in patients with primary hepatic cancer before and after intervention therapy,serum CA19-9 levels were detected by RIA,and serum SE-CAD and VEGF levels by ELISA in 32 patients and 35 healthy controls.The results showed that serum SE-CAD,CA19-9 and VEGF levels in patients before intervention therapy were significantly higher than those in control group(P<0.01).Twenty of 30 patients after 6 months of intervention therapy showed no sign of recurrence of cancer,and their serum SE-CAD,CA19-9 and VEGF levels dropped to normal range. The changes of serum SE-CAD,CA19-9 and VEGF levels in other 10 patients with recurrence of cancer were closely related to the disease process of primary hepatic cancer and might be regarded as useful values. |
| |
| Keywords: | Primary hepatic cancer Carbohydrate antigen19-9 Soluble epieyte cadherin Vascular endothelian growth factor |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
